(Q37053492)

17 August 2017

1 reference

title

Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? (English)

1 reference

toxic epidermal necrolysis

17 August 2017

main subject

1 reference

2

Brian J Nickoloff

1 reference

17 August 2017

Gerard J Abood

1

1 reference

17 August 2017

Richard L Gamelli

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Journal of Burn Care and Research

17 August 2017

published in

1 reference

17 August 2017

volume

29

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

269-276

1 reference

Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Epidemiologic approaches to the study of toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Long-term follow-up of patients treated for toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Burn unit management of toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Management of toxic epidermal necrolysis in a 15-year-old girl

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

SCORTEN: a severity-of-illness score for toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

SCORTEN overestimates mortality in the setting of a standardized treatment protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Plasmapheresis in toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Super high flux hemofiltration: a new technique for cytokine removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Drug-induced toxic epidermal necrolysis treated with cyclosporin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Toxic epidermal necrolysis in a burns centre: a 6-year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Treatment of toxic epidermal necrolysis and a review of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Toxic epidermal necrolysis: does immunoglobulin make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FBCR.0B013E31815F3658

10.1097/BCR.0B013E31815F3658

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference